Zymeworks
ZYME
12 hedge funds and large institutions have $14.8M invested in Zymeworks in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
1.32% less ownership
Funds ownership: 8.63% → 7.31% (-1.3%)
14% less funds holding
Funds holding: 14 → 12 (-2)
18% less capital invested
Capital invested by funds: $18M → $14.8M (-$3.18M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
Top Sellers
ZYME Hedge Fund Activity: Q3 2017 in Review
12 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Zymeworks (ZYME) for Q3 2017, worth a combined $14.8M — down 18% from $18M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ZYME and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $551K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $1.94M sold.
- 12 institutional investors held Zymeworks (ZYME) as of Q3 2017, down from 14 in Q2 2017.
- Funds reported $14.8M of Zymeworks stock for Q3 2017, down 18% quarter-over-quarter.
- 2 funds opened new Zymeworks positions in Q3 2017 and 4 closed out, a net change of -2 holders.
- The largest Zymeworks buyer in Q3 2017 was Royal Bank of Canada, an estimated $551K added.
- The largest Zymeworks seller in Q3 2017 was Cormorant Asset Management, an estimated $1.94M sold.
Based on aggregated 13F filings for Q3 2017.